(AOF) – Néovacs announces the superiority of its therapeutic messenger RNA (mRNA) vaccine, compared to the protein vaccine, in a preclinical trial in non-human primates for the treatment of allergies. This biotech which is developing new therapies for inflammatory and autoimmune diseases adds that in view of the results obtained with the mRNA approach, it has decided to extend the duration of this study to measure the effectiveness of mRNA type vaccines at long term (6 months).
According to Neovacs, the administration of the two vaccines was carried out without adverse effects in non-human primates and the study showed in both cases the induction of a neutralizing response against circulating cytokines IL-4 and IL-13. . The 3-month data also demonstrated significantly greater effectiveness of mRNA vaccines compared to protein vaccines.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
